Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...
When the campus is complete, it will produce several of Lilly’s APIs and genetic medicines to serve US patients.
More than $21 billion of Lilly’s domestic manufacturing commitments this decade have been directed to Indiana.¹ The Lebanon ...
Opportunities in the pharmaceutical API manufacturing market include leveraging rising demand for complex biologics, ...